Xenetic extends Scripps collaboration with $400k funding for DNase platform

Xenetic Biosciences, Inc.

Extended Research Funding & Option Agreement with Scripps Research by 12 months; total funding up to ~$400,000.
Initial $65k payment on Nov 1, 2024, followed by ~$65k monthly payments over 5 months.
Focus: systemic DNase I combined with CAR T-cell therapies for hematological cancers and melanoma.
Xenetic holds option to acquire exclusive license to new IP from the DNase research program.
Advancing DNase oncology platform toward Phase 1 for pancreatic carcinoma and solid tumors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.